-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|December 20, 2021

Understanding the Clinical Burden of Prostate Cancer

Author(s)John L. Fox, MD, MHA, Maria Lopes, MD, MS, Bhavesh Shah, RPh, BCOP

Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.

Episodes in this series

Expert on Prostate Cancer

EP. 1 Understanding the Clinical Burden of Prostate Cancer

Expert on Prostate cancer

EP. 2 Prostate Cancer’s Impact on Economy and Life

Expert on prostate cancer

EP. 3 Correlation Between Prostate Cancer and Cardiovascular Disease

Expert on prostate cancer

EP. 4 An Overview of the Prostate Cancer Treatment Landscape

Expert on prostate cancer

EP. 5 CVD Risk Associated With ADT in Prostate Cancer

Expert on prostate cancer

EP. 6 Prostate Cancer: Identifying Patients at Risk for CVD

Expert on prostate cancer

EP. 7 Prostate Cancer and CVD: Professional Society Guidelines

Expert on prostate cancer

EP. 8 Impact of CVD Risk on Cost of Care in Prostate Cancer

Expert on prostate cancer

EP. 9 CVD in Prostate Cancer: Risk-Bearing Practices and Alternative Payment Models

Expert on prostate cancer

EP. 10 Factors in Evaluating Therapy for Prostate Cancer

Expert on prostate cancer

EP. 11 What Evidence Is Needed to Further Define CVD Risk in Prostate Cancer?

Expert on prostate cancer

EP. 12 CVD Risk in Prostate Cancer: Quality Measures and Coverage Policy

Expert on prostate cancer

EP. 13 Multidisciplinary Care in Prostate Cancer and CVD Management

Expert on prostate cancer

EP. 14 CVD Risk in Prostate Cancer: Future Directions in Care

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Mary-Ellen Taplin, MD, FASCO | Image Credit: Dana-Farber Cancer Institute

Apalutamide Plus ADT Improves Outcomes in High-Risk Prostate Cancer: Mary-Ellen Taplin, MD

ByElla Hohmann, MS,Mary-Ellen Taplin, MD, FASCO

June 8th 2026

Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MD

ByElla Hohmann, MS,Tanya Barauskas Dorff, MD, FASCO

May 31st 2026

ARACOG Trial Links Enzalutamide to Greater Cognitive Decline Compared With Darolutamide: Alicia Morgans, MD, MPH

ByElla Hohmann, MS,Alicia Morgans, MD, MPH

May 30th 2026

Daniel George, MD | Image: Duke Health

For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials

March 3rd 2026

prostate cancer | Image: Dr Microbe Adobe

Radiopharmaceutical Medicare Use Jumps: ASTRO Abstracts Outline Delivery Models

February 20th 2026

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD